Verenigde Staten - Engels - NLM (National Library of Medicine)

avera mckennan hospital - captopril (unii: 9g64rsx1xd) (captopril - unii:9g64rsx1xd) - captopril 50 mg

Australië - Engels - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - captopril, quantity: 50 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose; maize starch; stearic acid; sodium starch glycollate - hypertension. treatment of hypertension. in using zedace, consideration should be given to the risk of neutropenia/ agranulocytosis (see precautions). zedace is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the hypotensive effects of captopril and thiazides are approximately additive. myocardial infraction. zedace may be used to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, manifested as an ejection fraction less than or equal to 40%, and to decrease the incidence of overt heart failure and subsequent hospitalisations for congestive heart failure in these patients. the efficacy data for the use of captopril following myocardial infarction are strongest for commencement of therapy beyond three days postinfarction. heart failure. treatment of heart failure. it is recommended that zedace be administered together with a diuretic in symptomatic patients. diabetic nephropathy. zedace is also indicated in the treatment of diabetic nephropathy in patients with type i insulin- dependent diabetes mellitus.

Verenigde Staten - Engels - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - captopril (unii: 9g64rsx1xd) (captopril - unii:9g64rsx1xd) - hypertension:  captopril tablets, usp are indicated for the treatment of hypertension. in using captopril, consideration should be given to the risk of neutropenia/agranulocytosis (see warnings ). captopril may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. in patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. heart failure: captopril tablets, usp are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. the beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. left ventricular dysfunction after myocardial infarction: captopril tablets, usp are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. diabetic nephropathy: captopril tablets, usp are indicated for the treatment of diabetic nephropathy (proteinuria ˃500 mg/day) in patients with type i insulin-dependent diabetes mellitus and retinopathy. captopril decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). in considering use of captopril, it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. in addition, ace inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see warnings: head and neck angioedema and intestinal angioedema ). captopril tablets are contraindicated in patients who are hypersensitive to this product or any other angiotensin-converting enzyme inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ace inhibitor). do not co-administer aliskiren with captopril in patients with diabetes (see precautions: drug interactions ). captopril tablets are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). do not administer captopril within 36 hours of switching to or from sacubitril/valsartan, a nepriltsin inhibitor (see precautions: drug interactions ).

Canada - Engels - Health Canada

laboratoires trianon inc. - captopril - tablet - 50mg - captopril 50mg - angiotensin-converting enzyme inhibitors

Verenigde Staten - Engels - NLM (National Library of Medicine)

rising pharma holdings, inc. - captopril (unii: 9g64rsx1xd) (captopril - unii:9g64rsx1xd), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - captopril and hydrochlorothiazide tablets are indicated for the treatment of hypertension. the blood pressure lowering effects of captopril and thiazides are approximately additive. this fixed combination drug may be used as initial therapy or substituted for previously titrated doses of the individual components. when captopril and hydrochlorothiazide are given together it may not be necessary to administer captopril in divided doses to attain blood pressure control at trough (before the next dose). also, with such a combination, a daily dose of 15 mg of hydrochlorothiazide may be adequate. treatment may, therefore, be initiated with captopril and hydrochlorothiazide tablets 25 mg/15 mg once daily. subsequent titration should be with additional doses of the components (captopril, hydrochlorothiazide) as single agents or as captopril and hydrochlorothiazide tablets 50 mg/15 mg, 25 mg/25 mg, or 50 mg/25 mg (see dosage and administration). in using captopril and hydrochlorothiazide, consideration

Verenigde Staten - Engels - NLM (National Library of Medicine)

a-s medication solutions - captopril (unii: 9g64rsx1xd) (captopril - unii:9g64rsx1xd) - captopril tablets, usp are indicated for the treatment of hypertension. in using captopril tablets, usp, consideration should be given to the risk of neutropenia/agranulocytosis (see warnings ). captopril tablets, usp may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. in patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. captopril tablets, usp are effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. captopril tablets, usp are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. the beneficial effect of captopril in heart failure does not requir

Canada - Engels - Health Canada

apotex inc - captopril - tablet - 50mg - captopril 50mg - angiotensin-converting enzyme inhibitors

Canada - Engels - Health Canada

mylan pharmaceuticals ulc - captopril - tablet - 50mg - captopril 50mg - angiotensin-converting enzyme inhibitors

Canada - Engels - Health Canada

teva canada limited - captopril - tablet - 50mg - captopril 50mg - angiotensin-converting enzyme inhibitors

Verenigde Staten - Engels - NLM (National Library of Medicine)

apotex corp. - captopril (unii: 9g64rsx1xd) (captopril - unii:9g64rsx1xd) - captopril 12.5 mg